CO2023016037A2 - Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos - Google Patents

Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos

Info

Publication number
CO2023016037A2
CO2023016037A2 CONC2023/0016037A CO2023016037A CO2023016037A2 CO 2023016037 A2 CO2023016037 A2 CO 2023016037A2 CO 2023016037 A CO2023016037 A CO 2023016037A CO 2023016037 A2 CO2023016037 A2 CO 2023016037A2
Authority
CO
Colombia
Prior art keywords
antibodies
tigit
methods
molecules
multispecific
Prior art date
Application number
CONC2023/0016037A
Other languages
English (en)
Inventor
Dhan Sidhartha Chand
Zahra Jawad
Olga Ignatovich
Nicola Anne Ramsay
Spencer Campbell
Beth Wensley
Emmanuel Cyrille Pascal Briend
K Mark Bushell
Benjamin Maxime Morin
Veronica Franciszka Ilkow
Original Assignee
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc filed Critical Agenus Inc
Publication of CO2023016037A2 publication Critical patent/CO2023016037A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción proporciona moléculas multiespecíficas que se unen específicamente a CD96 (por ejemplo, CD96 humano) y/o TIGIT (por ejemplo, TIGIT humano) y anticuerpos aislados que se unen específicamente a TIGIT (por ejemplo, TIGIT humano). También se proporcionan composiciones farmacéuticas que comprenden estas moléculas y anticuerpos multiespecíficos, ácidos nucleicos que codifican estas moléculas y anticuerpos multiespecíficos, vectores de expresión y células hospederas para preparar estas moléculas y anticuerpos multiespecíficos, y métodos para tratar a un sujeto mediante el uso de estas moléculas y anticuerpos multiespecíficos.
CONC2023/0016037A 2021-05-04 2023-11-23 Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos CO2023016037A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163201537P 2021-05-04 2021-05-04
PCT/US2022/072099 WO2022236276A2 (en) 2021-05-04 2022-05-04 Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2023016037A2 true CO2023016037A2 (es) 2023-11-30

Family

ID=83933041

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0016037A CO2023016037A2 (es) 2021-05-04 2023-11-23 Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos

Country Status (15)

Country Link
US (2) US11718669B2 (es)
EP (1) EP4333893A2 (es)
JP (1) JP2024516843A (es)
KR (1) KR20240006054A (es)
CN (1) CN117425494A (es)
AR (1) AR125753A1 (es)
AU (1) AU2022271331A1 (es)
BR (1) BR112023022319A2 (es)
CA (1) CA3217289A1 (es)
CL (1) CL2023003244A1 (es)
CO (1) CO2023016037A2 (es)
IL (1) IL308157A (es)
PE (1) PE20240369A1 (es)
TW (1) TW202304965A (es)
WO (1) WO2022236276A2 (es)

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
ES2772674T3 (es) 2005-05-12 2020-07-08 Zymogenetics Inc Composiciones y métodos para modular respuestas inmunitarias
KR101924831B1 (ko) 2008-04-09 2018-12-05 제넨테크, 인크. 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법
EP3798237A1 (en) 2010-03-05 2021-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
WO2013160396A1 (en) 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
US9090694B2 (en) * 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
KR20150018604A (ko) 2012-06-06 2015-02-23 온코메드 파마슈티칼스, 인크. 히포 경로를 조절하는 결합제 및 그의 용도
RS60826B1 (sr) 2013-07-16 2020-10-30 Hoffmann La Roche Postupci lečenja kancera upotrebom antagonista vezivanja pd-1 ose i tigit inhibitora
HUE063307T2 (hu) 2013-08-22 2024-01-28 The Council Of The Queensland Rák és vírusfertõzések kezelésére szolgáló immunreceptor-moduláció
WO2015035112A1 (en) 2013-09-05 2015-03-12 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
MX2016003617A (es) * 2013-09-30 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
RU2690670C2 (ru) 2014-03-12 2019-06-05 Ида Рисерч Энд Дивелопмент Ко., Лтд Снижение уровней или активности системных регуляторных т-клеток для лечения заболевания или повреждения цнс
EP3119913B1 (en) 2014-03-21 2021-01-06 The Brigham and Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
TW201623333A (zh) 2014-05-13 2016-07-01 Chugai Pharmaceutical Co Ltd 對具有免疫抑制機能之細胞的ｔ細胞重定向抗原結合分子
CN112546230A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
PE20170140A1 (es) 2014-07-16 2017-03-30 Genentech Inc Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
IL250583B (en) 2014-08-19 2022-07-01 Merck Sharp & Dohme Anti-tigit antibodies
MA40035A (fr) 2014-10-14 2016-04-21 Dana Farber Cancer Inst Inc Molécules d'anticorps de pd-l1 et leurs utilisations
AU2015335607B2 (en) 2014-10-24 2020-04-23 Calidi Biotherapeutics (Nevada), Inc. Combination immunotherapy approach for treatment of cancer
SG11201703376QA (en) 2014-11-06 2017-05-30 Genentech Inc Combination therapy comprising ox40 binding agonists and tigit inhibitors
MA40662B1 (fr) 2014-12-23 2020-12-31 Bristol Myers Squibb Co Anticorps contre tigit
JP2018516847A (ja) 2015-03-25 2018-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 生体高分子薬を送達するための組成物及び方法
WO2016180781A1 (en) 2015-05-08 2016-11-17 Michele Maio Combination therapy of mesothelioma
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
EA201890162A1 (ru) 2015-06-29 2018-07-31 Бристол-Маерс Сквибб Компани Антитела к cd40 с повышенной агонистической активностью
EP3328363A4 (en) 2015-07-31 2019-08-21 Tarveda Therapeutics, Inc. COMPOSITIONS AND METHODS OF IMMUNOMODULATION
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
JP6976241B2 (ja) 2015-08-14 2021-12-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ｔｉｇｉｔ抗体
KR20220131277A (ko) 2015-09-01 2022-09-27 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
EP3344658B1 (en) 2015-09-02 2022-05-11 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
AU2016322934A1 (en) 2015-09-14 2018-04-12 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta
WO2017053748A2 (en) 2015-09-25 2017-03-30 Genentech, Inc. Anti-tigit antibodies and methods of use
ES2910027T3 (es) 2015-10-01 2022-05-11 Potenza Therapeutics Inc Proteínas de unión a antígeno anti-TIGIT y métodos de uso de las mismas
WO2017062619A2 (en) 2015-10-08 2017-04-13 Macrogenics, Inc. Combination therapy for the treatment of cancer
JP6821688B2 (ja) 2015-10-09 2021-01-27 ミルテニー・バイオテク・テクノロジー・インコーポレイテッドＭｉｌｔｅｎｙｉ Ｂｉｏｔｅｃ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． キメラ抗原受容体および使用方法
EP3402517A4 (en) 2016-01-15 2020-01-15 RFEMB Holdings, LLC IMMUNOTHERAPY OF CANCER
MX2018010485A (es) 2016-03-04 2019-01-10 Jn Biosciences Llc Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit).
JP2019519548A (ja) 2016-06-17 2019-07-11 ヴァリアン メディカル システムズ インコーポレイテッド 放射線処置と組み合わせた免疫調節剤
WO2017223085A2 (en) 2016-06-20 2017-12-28 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
KR102450208B1 (ko) 2016-08-17 2022-10-05 컴퓨젠 엘티디. 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
MX2019002925A (es) 2016-09-15 2019-09-05 Idera Pharmaceuticals Inc Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
US11230596B2 (en) 2016-11-30 2022-01-25 Mereo Biopharma 5, Inc. Methods for treatment of cancer comprising TIGIT-binding agents
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
WO2018128939A1 (en) 2017-01-05 2018-07-12 Gensun Biopharma Inc. Checkpoint regulator antagonists
SG10202103227YA (en) 2017-02-28 2021-04-29 Seattle Genetics Inc Anti-tigit antibodies
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
DK3618863T3 (da) 2017-05-01 2023-08-21 Agenus Inc Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
JP7402693B2 (ja) 2017-05-02 2023-12-21 メルク・シャープ・アンド・ドーム・エルエルシー 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
CN110997720A (zh) 2017-07-27 2020-04-10 Iteos治疗公司 抗tigit抗体
JP7317272B2 (ja) 2017-09-29 2023-07-31 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｔｉｇｉｔ抗体、その抗原結合断片及びその医療用途 本願は、２０１９年９月２９日に出願された出願番号ｃｎ２０１７１０９０８５６５．３に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。
CN110914304B (zh) 2017-11-10 2022-07-26 江苏恒瑞医药股份有限公司 Cd96抗体、其抗原结合片段及医药用途
CA3082280A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
TW202400654A (zh) * 2017-12-30 2024-01-01 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
AU2019207296A1 (en) 2018-01-15 2020-07-16 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against TIGIT
US20210363243A1 (en) 2018-02-01 2021-11-25 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
CA3086936C (en) 2018-02-06 2022-11-29 I-Mab Biopharma Us Limited Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
KR20200135313A (ko) 2018-02-26 2020-12-02 제넨테크, 인크. 항-tigit 및 항-pd-l1 길항제 항체에 의한 치료를 위한 투약
MX2020008795A (es) 2018-02-28 2020-10-08 Yuhan Corp Anti cuerpos anti tigit y usos de los mismos.
MX2021005008A (es) * 2018-10-31 2021-06-15 Delinia Inc Moduladores de celulas t reguladoras multivalentes.
EP3938396A1 (en) * 2019-03-11 2022-01-19 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
AU2020308463A1 (en) * 2019-06-26 2022-02-17 Ap Biosciences, Inc. Antibodies for T-cell activation
PE20221151A1 (es) 2019-08-30 2022-07-18 Agenus Inc Anticuerpos anti-cd96 y sus metodos de uso
US20220389095A1 (en) * 2021-05-04 2022-12-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof

Also Published As

Publication number Publication date
AU2022271331A9 (en) 2023-11-09
WO2022236276A2 (en) 2022-11-10
AR125753A1 (es) 2023-08-09
CN117425494A (zh) 2024-01-19
BR112023022319A2 (pt) 2024-02-20
CA3217289A1 (en) 2022-11-10
US20240141039A1 (en) 2024-05-02
US11718669B2 (en) 2023-08-08
WO2022236276A3 (en) 2023-01-19
EP4333893A2 (en) 2024-03-13
TW202304965A (zh) 2023-02-01
PE20240369A1 (es) 2024-03-04
CL2023003244A1 (es) 2024-04-19
IL308157A (en) 2024-01-01
KR20240006054A (ko) 2024-01-12
JP2024516843A (ja) 2024-04-17
US20230014036A1 (en) 2023-01-19
AU2022271331A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
CY1123932T1 (el) Δομες πολυειδικου αντισωματος
AR114275A1 (es) Anticuerpos anti-cd73 y métodos de uso de los mismos
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
BR112022014667A2 (pt) Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
CO2019001367A2 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
BR112018007046A2 (pt) anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, molécula de polinucleotídeo isolado, vetor, célula, e, métodos para inibir o crescimento de um tumor ou de uma célula tumoral e para tratar uma doença ou distúrbio.
EA201892616A1 (ru) Антитела к pd1 и lag3 для лечения злокачественного новообразования
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
AR109276A1 (es) ANTICUERPOS ANTI-hCTLA 4
BR112017007093A2 (pt) composições e métodos de uso para aumento da resposta imune e terapia do câncer
CO2022001977A2 (es) Anticuerpos anti-cd96 y sus métodos de uso
UY37635A (es) Anticuerpos anti phf-tau y sus usos
PE20171764A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123
DOP2015000110A (es) Anticuerpos anti-ceacam5 y usos de estos
BR112016030462A2 (pt) moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo
AR115389A1 (es) Anticuerpo antagonista de cd73
CL2021000028A1 (es) Anticuerpo multiespecifico (divisional de solicitud 937-2020).
BR112015017548A8 (pt) construção de anticorpo multiespecífico isolado, sequência de ácido nucléico, vetor, célula hospedeira, processo para a produção da construção de anticorpo, composição farmaceutica, uso da construção de anticorpo e kit
BR112022004047A2 (pt) Proteínas de ligação multiespecíficas para o tratamento de câncer
BR112017023692A2 (pt) moléculas imunoterapêuticas glican-dependentes
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
UY39416A (es) Moléculas de direccionamiento inmunes multiespecíficas y usos de estas